DexCom Revenue vs. Shares Owned By Institutions
| DXCM Stock | USD 77.99 0.11 0.14% |
Total Revenue | First Reported 2003-12-31 | Previous Quarter 1 B | Current Value 994.2 M | Quarterly Volatility 305.2 M |
For DexCom profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DexCom to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DexCom Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DexCom's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DexCom Inc over time as well as its relative position and ranking within its peers.
DexCom |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
DexCom Inc Shares Owned By Institutions vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining DexCom's current stock value. Our valuation model uses many indicators to compare DexCom value to that of its competitors to determine the firm's financial worth. DexCom Inc is rated # 5 in revenue category among its peers. It is one of the top stocks in shares owned by institutions category among its peers . The ratio of Revenue to Shares Owned By Institutions for DexCom Inc is about 37,393,414 . At this time, DexCom's Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value DexCom by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.DexCom Revenue vs. Competition
DexCom Inc is rated # 5 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 88.11 Billion. DexCom holds roughly 3.62 Billion in revenue claiming about 4% of equities under Health Care industry.
DexCom Shares Owned By Institutions vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
DexCom |
| = | 3.62 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
DexCom |
| = | 96.87 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
DexCom Shares Owned By Institutions Comparison
DexCom is currently under evaluation in shares owned by institutions category among its peers.
DexCom Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in DexCom, profitability is also one of the essential criteria for including it into their portfolios because, without profit, DexCom will eventually generate negative long term returns. The profitability progress is the general direction of DexCom's change in net profit over the period of time. It can combine multiple indicators of DexCom, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -16.7 M | -15.9 M | |
| Operating Income | 597.7 M | 627.6 M | |
| Net Income | 541.5 M | 568.6 M | |
| Income Tax Expense | 168.9 M | 177.3 M | |
| Income Before Tax | 710.4 M | 745.9 M | |
| Total Other Income Expense Net | 112.7 M | 118.3 M | |
| Net Income From Continuing Ops | 541.5 M | 568.6 M | |
| Non Operating Income Net Other | 20.7 M | 21.7 M | |
| Net Income Applicable To Common Shares | 392.4 M | 412 M | |
| Interest Income | 135 M | 141.8 M | |
| Net Interest Income | 114.7 M | 120.4 M | |
| Change To Netincome | 167.8 M | 84.3 M | |
| Net Income Per Share | 1.40 | 1.47 | |
| Income Quality | 1.38 | 1.45 | |
| Net Income Per E B T | 0.76 | 0.78 |
DexCom Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on DexCom. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DexCom position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DexCom's important profitability drivers and their relationship over time.
Use DexCom in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.DexCom Pair Trading
DexCom Inc Pair Trading Analysis
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your DexCom position
In addition to having DexCom in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
To fully project DexCom's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DexCom Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DexCom's income statement, its balance sheet, and the statement of cash flows.